Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Date	Fund	Action	%
2023/09/20	ARKK	Buy	0.0402
2023/09/20	ARKG	Buy	0.0351
2023/09/19	ARKK	Buy	0.0553
2023/09/19	ARKG	Buy	0.0566
2023/08/31	ARKG	Buy	0.012
2023/08/30	ARKK	Buy	0.0036
2023/08/30	ARKG	Buy	0.0025
2023/08/28	ARKK	Buy	0.0011
2023/08/28	ARKG	Buy	0.0018
2023/08/25	ARKK	Buy	0.0025
2023/08/25	ARKG	Buy	0.0146
2023/08/24	ARKK	Buy	0.0347
2023/08/24	ARKG	Buy	0.063
2023/08/23	ARKK	Buy	0.011
2023/08/23	ARKG	Buy	0.02
2023/08/22	ARKK	Buy	0.0001
2023/08/22	ARKG	Buy	0.0001
2023/08/21	ARKK	Buy	0.0045
2023/08/21	ARKG	Buy	0.0086
2023/08/17	ARKK	Buy	0.0014
2023/08/17	ARKG	Buy	0.0025
2023/08/16	ARKK	Buy	0.0061
2023/08/16	ARKG	Buy	0.0118
2023/08/15	ARKK	Buy	0.0044
2023/08/15	ARKG	Buy	0.0103
2023/08/14	ARKK	Buy	0.0004
2023/08/14	ARKG	Buy	0.0009
2023/08/11	ARKK	Buy	0.0036
2023/08/11	ARKG	Buy	0.0069
2023/08/10	ARKK	Buy	0.0078